ITOS250117C9000
- 0.05
- 0.000.00%
ITeos Therapeutics Newsroom
Express News | Iteos Therapeutics Inc - Eos-215 Ind Submission Anticipated in 1Q25
Express News | Iteos Therapeutics Inc - Eos-984 Phase 1 Monotherapy and Pd-1 Combination Data Expected in 2H25
Express News | Iteos Therapeutics Inc - Cash Balance of $683.9 Million Expected to Provide Runway Through 2027
Express News | Iteos Announces 2025 Strategic Priorities and Anticipated Milestones
ITeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ITeos Therapeutics Options Spot-On: On December 30th, 150.59K Contracts Were Traded, With 35,558 Open Interest
On December 30th ET, $ITeos Therapeutics(ITOS.US)$ had active options trading, with a total trading volume of 150.59K options for the day, of which put options accounted for 0.0% of the total
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $19
ITeos Therapeutics Price Target Lowered to $19 From $31 at Wells Fargo
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $21
Strategic Focus on Belrestotug Drives Buy Rating for ITeos Therapeutics With Adjusted Price Target of $21
Express News | Iteos Therapeutics Inc : Piper Sandler Cuts Target Price to $16 From $36
ITeos Therapeutics Says Deprioritizing Cancer Drug Candidate Inupadenant
ITeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data From Inupadenant at ESMO Immuno-Oncology Congress
Express News | Iteos Therapeutics Presents Interim a2a-005 Clinical Trial Data, Translational, and Preclinical Data From Inupadenant at Esmo Immuno-Oncology Congress
ITeos to Participate in Upcoming Investor Conferences
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
ITeos Therapeutics Analyst Ratings
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46